Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysisBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e4959 (Published 20 July 2012) Cite this as: BMJ 2012;345:e4959
There are several inaccuracies in this Research paper by Karagiannis and colleagues (BMJ 2012;344:e1369, doi:10.1136/bmj.e1369). In the final paragraph of the section “Glycaemic efficacy,” the risk ratio in favour of GLP-1 agonists should have been 1.82, 95% confidence interval 1.50 to 2.21; I2=26% [not “1.33, 1.09 to 1.63; I2=26%”].
There are also some errors in figure 3. The first and second column headings under “Events/total” should be swapped, so that the first column is headed “Active comparator” and the second column is headed “DPP-4 inhibitor.” The four row headings of the study groups on the left should also be changed to read, in descending order: “Monotherapy: metformin v DPP-4 inhibitor;” “Combined with metformin: sulfonylurea v DPP-4 inhibitor;” “Combined with metformin: pioglitazone v DPP-4 inhibitor;” and “Combined with metformin: GLP-1 agonist v DPP-4 inhibitor.” These were typographical errors and do not affect the interpretation and conclusions of the paper.
Cite this as: BMJ 2012;345:e4959